Payment overview · 2025
General Payments
$386.70
18 reported records · 7 companies
Healthcare provider profile · identity verified
Jeremy Wayne Johnson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1457521874
Verified facts
What the public records show
CMS Open Payments records show Jeremy Wayne Johnson, D.O. received $386.70 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.69 | 49.3% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $58.57 | 15.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.77 | 9.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.70 | 9.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.48 | 7.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.79 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.70 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.70 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $190.69 | 9 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $58.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 258 | 69 |
| Gabapentin | Gabapentin | 225 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 46 |
| Alprazolam | Alprazolam | 199 | 27 |
| Lisinopril | Lisinopril | 197 | 45 |
| Metformin Hcl | Metformin Hcl | 185 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 38 |
| Trazodone Hcl | Trazodone Hcl | 131 | 25 |
| Potassium Chloride | Potassium Chloride | 128 | 29 |
| Furosemide | Furosemide | 124 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 27 |
| Meloxicam | Meloxicam | 113 | 23 |
| Clonazepam | Clonazepam | 111 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 22 |
| Omeprazole | Omeprazole | 102 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 22 |
| Tramadol Hcl | Tramadol Hcl | 96 | 16 |
| Montelukast Sodium | Montelukast Sodium | 92 | 19 |
| Pregabalin | Pregabalin | 78 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 18 |
| Losartan Potassium | Losartan Potassium | 76 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 16 |
| Diazepam | Diazepam | 71 | 11 |
| Carvedilol | Carvedilol | 70 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 17 |
| Eliquis | Apixaban | 62 | 12 |
| Spironolactone | Spironolactone | 62 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 17 |
| Ozempic | Semaglutide | 60 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Trulicity | Dulaglutide | 47 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Prednisone | Prednisone | 40 | 17 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 14 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amoxapine | Amoxapine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.70 · 18 records | ABBVIE INC. | Auvelity, Cologuard Collection Kit, NEXPLANON, OTEZLA, Qelbree, REPATHA, VRAYLAR, ZURZUVAE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error